Roswell Park
@roswellpark
Roswell Park brings together the best medical & scientific minds in cancer care. We are the only NCI-designated comprehensive cancer center in Upstate New York.
ID: 16044589
http://www.roswellpark.org 29-08-2008 17:12:45
32,32K Tweet
20,20K Followers
1,1K Following
Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease Roswell Park #oncology onclive.com/view/final-res…
On #NationalDogDay, we’re shining a spotlight on one of Roswell Park’s furry heroes: Murphy, who has been working here as a therapy dog since 2017. Thank you to Ian MacKay & Paul Dawson from the Buffalo Bandits for asking Murphy the burning questions we’ve all been curious about! 🧡
Let’s give it up for Desmond! 🎉 He’s just finished his treatment for high risk T-cell acute lymphoblastic leukemia, and this is his second time ringing our victory bell.🔔🎗️🎗️🎗️🎗️🎗️ We couldn’t be happier to celebrate this incredible milestone with him. 🧡 Courage of Carly
Very excited to have Dr. Jen Mongiovi as our latest Emerging Leaders Seminar speaker Roswell Park! Always love when our great students come back and show us their amazing new work!
At today's Functional Screens and Assay Development WG meeting, Dr. David Goodrich from Roswell Park shared his recent work on screening for regulators of cancer cell adaptability.
"Understanding prostate response to hormone therapy and androgen receptor signaling inhibitors is crucial for enhancing long-term survival for #ProstateCancer patients,” noted Dean Tang, PhD, at Roswell Park. ow.ly/IWif50T7T1l
Buffalo Goes Gray Mission Possible gala happened in May and they recently presented a check for $30,000 to Michael Ciesielski, PhD, and his team to further bran cancer research at Roswell Park! Thank you to everyone who supports brain cancer awareness and the BGG organization.
CONGRESS | #SOHO2024 Eunice Wang Roswell Park provides an update on menin inhibitors for the treatment of #AML. Wang shares the latest clinical trial data for investigational menin inhibitors; noting the clear clinical activity but short duration of response, driving further
Ongoing research may solidify the roles of oral SERDs, PARP inhibitors, and additional targeted therapies, particularly after progression in CDK4/6 inhibitors, in the management of HR+ breast cancer. Shipra Gandhi Roswell Park #bcsm #oncology #MedTwitter onclive.com/view/the-hr-po…